Houston, TX – -The National Diversity Council is proud to present “Leading While Diverse: The Case for Diversity in Corporate Governance,” a comprehensive research report ranking top pharmaceutical companies based on their diversity in executive positions and boards of directors. The reputation of multinational pharmaceutical companies is currently one of the lowest, second only to health insurance companies. This report presents a business case for the importance of improving diversity in executive leadership.
“This type of report is long overdue in the pharmaceutical industry,” said Dennis Kennedy, Founder and Chair of the National Diversity Council. “Bringing attention to the need for diversity and increasing inclusion efforts in global market leadership will make an immense contribution to overall success in business.”
The National Diversity Council ranks the 25 top selling pharmaceutical companies based on the inclusivity of women and people of color. The comprehensive data breakdown focuses on leadership in relation to (1) white women; (2) women of color; (3) people of color and (4) white men. An in depth analysis of their top leadership positions reveal which companies make the diversity mark and which companies fall short.
Using a census-based biographical approach, the National Diversity Council analyzed the diversity at the top of each company. Abbvie, Merck U.S.A, and Eli Lilly toped the list for People of Color Diversity and Inclusion Rankings (PIDR). Each company’s score was based on people of color on the board of directors and in executive positions. Abbvie claimed the top spot with a 29.2% PIDR. Merck U.S.A and Eli Lilly followed with a 24.2% and 18.2% ranking, respectively.
Gender Inclusion is also a major factor in ranking the diversity in the pharmaceutical industry. In order to calculate the Gender Diversity and Inclusion Ranking (GDIR), the National Diversity Council identified the number of women on the board of directors and in executive positions. Novo Nordisk surpassed all other companies with a 33.2% GDIR. AstraZeneca trailed closely with at 32.3% followed by Eli Lilly at 29.9%.
The National Diversity Council hopes that this type of report will not only make companies aware of where they stand, but encourage them to make a conscious effort to increase diversity within their organizations. The report offers a number of recommendations such as building and maintaining stronger networks and relations with associations that promote the advancement of historically marginalized groups. These recommendations suggest that this type of improvement will assist pharmaceutical companies with maintaining a competitive edge and enhancing their brand for many years to come.
For more information or to purchase “Leading While Diverse” please contact Lucy Carrillo at [email protected]ationldiversitycouncil.org.